BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 2937839)

  • 21. Complement: activation, consequences, and control.
    James K
    Am J Med Technol; 1982 Sep; 48(9):735-42. PubMed ID: 6215861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural and functional characterization of complement C4 and C1s-like molecules in teleost fish: insights into the evolution of classical and alternative pathways.
    Boshra H; Gelman AE; Sunyer JO
    J Immunol; 2004 Jul; 173(1):349-59. PubMed ID: 15210793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistently circulating C3 nephritic factor (C3 NeF)-stabilized alternative pathway C3 convertase (C3 CoF) in serum of an 11-year-old girl with meningococcal septicemia--simultaneous occurrence with free C3 NeF.
    Wahn V; Müller W; Rieger C; Rother U
    Pediatr Res; 1987 Aug; 22(2):123-9. PubMed ID: 3658535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Killing of the S and Re forms of Salmonella minnesota via the classical pathway of complement activation in guinea-pig and human sera.
    Clas F; Loos M
    Immunology; 1980 Aug; 40(4):547-56. PubMed ID: 6776034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
    Webster GF; McArthur WP
    Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative pathway of complement.
    Pangburn MK
    Methods Enzymol; 1988; 162():639-53. PubMed ID: 2976114
    [No Abstract]   [Full Text] [Related]  

  • 28. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of the alternative complement pathway by IgM antibody reacted on paragloboside incorporated into liposome membrane.
    Okada H; Okada N; Yasuda T
    Mol Immunol; 1983 Apr; 20(4):499-500. PubMed ID: 6865961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sheep serum complement sensitisation of sheep erythrocyte-rabbit antibody complexes for haemolysis by guinea-pig complement plus EDTA or Mg2+-EGTA.
    Jonas W; Stankiewicz M
    Arch Immunol Ther Exp (Warsz); 1986; 34(4):451-60. PubMed ID: 3099725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The mechanism of activation of the alternative pathway of complement by cell-bound C4b.
    Farries TC; Steuer KL; Atkinson JP
    Mol Immunol; 1990 Nov; 27(11):1155-61. PubMed ID: 2247091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Covalent association of C3b with C4b within C5 convertase of the classical complement pathway.
    Takata Y; Kinoshita T; Kozono H; Takeda J; Tanaka E; Hong K; Inoue K
    J Exp Med; 1987 Jun; 165(6):1494-507. PubMed ID: 3495629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.
    Barilla-LaBarca ML; Liszewski MK; Lambris JD; Hourcade D; Atkinson JP
    J Immunol; 2002 Jun; 168(12):6298-304. PubMed ID: 12055245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel.
    Truedsson L; Sjöholm AG; Laurell AB
    Acta Pathol Microbiol Scand C; 1981 Jun; 89(3):161-6. PubMed ID: 7032205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
    Asghar SS; de Koster A; van der Helm HJ
    Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement.
    Kew RR; Ghebrehiwet B; Janoff A
    J Clin Invest; 1985 Mar; 75(3):1000-7. PubMed ID: 3156879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for restriction of the ability of complement to lyse homologous erythrocytes.
    Houle JJ; Hoffmann EM
    J Immunol; 1984 Sep; 133(3):1444-52. PubMed ID: 6430999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.